Octreotide, sandostatin LAR, lanreotide, vapreotide, somatostatin are names for the same drug. The following are articles from the Netherlands' experience using Lanreotide gel given subcutaneously every 28 days. There is a (6) six month study with lanreotide that showed a percentage reduction in PLD Polycystic Liver Disease. A second article is a case study of two (2) Polycystic Liver Disease patients that had a significant reduction in their liver cyst volume and a diminishing of ascites.
Choose LANREOTIDE article Lanreotide two (2) case studies: Somatostatin analogues reduce liver volume PLD Lanreotide report of clinical trial in Netherlands Lanreotide crossover study on the effects of lanreotide Autogel and octreotide long-acting Lanreotide Autogel Octreotide reduces liver cysts in the PLD animal model Liver cysts have hormone receptors, growth hormone receptors,insulin like receptors Octreotide blocks all 3 abstract of above article Clinical trial Mayo sandostatin LAR IM 28 days USA Clinical trial Netherlands and Belgium with lanreotide clinical trial subcutaneous 28 days Clinical trial in Italy somatostatin Somatostatin Italian study reduces kidney cysts: safety and efficacy of somatostatin in ADPKD.